Natera, Inc. (NASDAQ:NTRA) Stock Position Lowered by Zurcher Kantonalbank Zurich Cantonalbank

Key Points

• Zurcher Kantonalbank reduced its stake in Natera, Inc. by 13.3%, now holding 26,205 shares worth approximately $3.7 million.
• Natera's stock price dropped 5.2%, and its shares are currently trading at around $133.66, with a market cap of $18.25 billion.
• The company reported a negative EPS of ($0.50) for the recent quarter, exceeding analysts' expectations, and a 36.5% increase in revenue year-over-year, totaling $501.83 million.

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 13.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 26,205 shares of the medical research company's stock after selling 4,026 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Natera were worth $3,706,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HighPoint Advisor Group LLC grew its holdings in shares of Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after acquiring an additional 468 shares in the last quarter. Amalgamated Bank boosted its position in Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after purchasing an additional 740 shares during the last quarter. GAMMA Investing LLC grew its stake in Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares in the last quarter. Teza Capital Management LLC acquired a new position in Natera in the 4th quarter worth about $221,000. Finally, Asset Management One Co. Ltd. purchased a new stake in shares of Natera during the 1st quarter worth about $6,753,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Down 5.2%

Shares of NASDAQ:NTRA opened at $133.66 on Friday. The company has a market cap of $18.25 billion, a price-to-earnings ratio of -90.92 and a beta of 1.73. The business has a 50 day moving average price of $157.54 and a 200 day moving average price of $156.09. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same period in the previous year, the company earned ($0.56) earnings per share. The company's quarterly revenue was up 36.5% compared to the same quarter last year. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the sale, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 6,111 shares of Natera stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the sale, the chief executive officer directly owned 179,071 shares in the company, valued at approximately $28,132,054.10. This trade represents a 3.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,936 shares of company stock valued at $7,483,846 in the last 90 days. 7.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NTRA shares. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research note on Monday. UBS Group boosted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Piper Sandler increased their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Barclays raised their price target on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One research analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $183.76.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.